Clinical Trial Update: Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating efficacy and safety of 177Lu-Dotatate PRRT in metastatic gastroenteropancreatic neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors
• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN